Huapont Life SciencesLtd Past Earnings Performance
Past criteria checks 0/6
Huapont Life SciencesLtd's earnings have been declining at an average annual rate of -12.5%, while the Chemicals industry saw earnings growing at 6.3% annually. Revenues have been growing at an average rate of 4.3% per year. Huapont Life SciencesLtd's return on equity is 2.8%, and it has net margins of 2%.
Key information
-12.5%
Earnings growth rate
-12.4%
EPS growth rate
| Chemicals Industry Growth | 12.1% |
| Revenue growth rate | 4.3% |
| Return on equity | 2.8% |
| Net Margin | 2.0% |
| Next Earnings Update | 29 Oct 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How Huapont Life SciencesLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 11,648 | 228 | 2,467 | 398 |
| 31 Mar 24 | 11,535 | 281 | 2,573 | 412 |
| 31 Dec 23 | 11,595 | 302 | 2,557 | 419 |
| 30 Sep 23 | 11,904 | 221 | 2,621 | 425 |
| 30 Jun 23 | 12,401 | 261 | 2,798 | 413 |
| 31 Mar 23 | 12,809 | 442 | 2,783 | 403 |
| 01 Jan 23 | 13,232 | 433 | 2,911 | 385 |
| 30 Sep 22 | 13,983 | 864 | 2,903 | 394 |
| 30 Jun 22 | 13,383 | 875 | 2,784 | 348 |
| 31 Mar 22 | 13,011 | 715 | 2,811 | 339 |
| 01 Jan 22 | 12,431 | 668 | 2,777 | 329 |
| 30 Sep 21 | 11,618 | 658 | 2,725 | 308 |
| 30 Jun 21 | 11,446 | 687 | 2,690 | 323 |
| 31 Mar 21 | 11,441 | 690 | 2,662 | 323 |
| 01 Jan 21 | 10,876 | 652 | 2,544 | 324 |
| 30 Sep 20 | 10,485 | 627 | 2,746 | 285 |
| 30 Jun 20 | 10,248 | 642 | 2,858 | 294 |
| 31 Mar 20 | 9,893 | 603 | 2,715 | 296 |
| 31 Dec 19 | 10,091 | 620 | 2,768 | 288 |
| 30 Sep 19 | 10,214 | 525 | 2,792 | 331 |
| 30 Jun 19 | 10,515 | 491 | 2,614 | 372 |
| 31 Mar 19 | 10,319 | 510 | 2,515 | 339 |
| 01 Jan 19 | 10,574 | 506 | 2,403 | 349 |
| 30 Sep 18 | 10,925 | 534 | 2,259 | 334 |
| 30 Jun 18 | 9,973 | 483 | 1,961 | 348 |
| 31 Mar 18 | 9,866 | 457 | 1,939 | 289 |
| 31 Dec 17 | 9,183 | 506 | 1,771 | 211 |
| 30 Sep 17 | 8,234 | 415 | 1,643 | 137 |
| 30 Jun 17 | 8,046 | 486 | 1,621 | 0 |
| 31 Mar 17 | 7,606 | 540 | 1,505 | 0 |
| 31 Dec 16 | 7,093 | 567 | 1,443 | 0 |
| 30 Sep 16 | 6,403 | 658 | 1,296 | 0 |
| 30 Jun 16 | 6,187 | 654 | 1,322 | 0 |
| 31 Mar 16 | 6,172 | 620 | 1,288 | 0 |
| 31 Dec 15 | 6,174 | 637 | 1,236 | 0 |
| 30 Sep 15 | 5,834 | 651 | 1,088 | 0 |
| 30 Jun 15 | 5,587 | 594 | 1,008 | 0 |
| 31 Mar 15 | 5,278 | 544 | 914 | 0 |
| 31 Dec 14 | 4,867 | 429 | 863 | 0 |
| 30 Sep 14 | 5,038 | 412 | 834 | 0 |
| 30 Jun 14 | 4,901 | 376 | 745 | 0 |
| 31 Mar 14 | 4,572 | 314 | 694 | 0 |
| 31 Dec 13 | 4,465 | 303 | 668 | 0 |
Quality Earnings: 002004 has a large one-off loss of CN¥186.2M impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: 002004's current net profit margins (2%) are lower than last year (2.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 002004's earnings have declined by 12.5% per year over the past 5 years.
Accelerating Growth: 002004's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 002004 had negative earnings growth (-12.4%) over the past year, making it difficult to compare to the Chemicals industry average (-4.7%).
Return on Equity
High ROE: 002004's Return on Equity (2.8%) is considered low.